| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,020 | 4,100 | 15.11. | |
| 4,020 | 4,100 | 13.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein | 2 | GlobeNewswire (USA) | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| 30.10. | LEADS BIOLABS-B Completes First Dosing of Systemic Lupus Erythematosus Patient in Part B of Phase I Study for LBL-047 | 3 | AASTOCKS | ||
| 30.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PART B OF LBL-047 PHASE I STUDY COMPLETES FIRST DOSING OF A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS; ... | 1 | HKEx | ||
| 26.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PRESENTATION OF UPDATED CLINICAL AND TRANSLATIONAL DATA OF LBL-024 FOR EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, ... | - | HKEx | ||
| 26.10. | LEADS BIOLABS-B Preparing Phase III Clinical Trial for LBL-034 | 4 | AASTOCKS | ||
| 25.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform | 5 | GlobeNewswire (USA) | ||
| 20.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study | 1 | GlobeNewswire (USA) | ||
| 20.10. | LEADS BIOLABS-B Phase II Study of Leadsin for First-line Gastric Cancer Treatment Enters Expansion Stage | 1 | AASTOCKS | ||
| 20.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AS FIRST-LINE TREATMENT FOR ... | - | HKEx | ||
| 19.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig and LBL-034 Featured in Six Abstracts at 2026 ESMO Congress | 1 | GlobeNewswire (USA) | ||
| 19.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT ABSTRACTS OF SIX STUDIES PUBLISHED AT 2026 ESMO | 1 | HKEx | ||
| 16.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer | 1 | GlobeNewswire (USA) | ||
| 16.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ... | 3 | HKEx | ||
| 12.10. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer | 1 | GlobeNewswire (USA) | ||
| 12.10. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA ... | 1 | HKEx | ||
| 28.09. | LEADS BIOLABS CO., LTD.: Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition | 5 | GlobeNewswire (USA) | ||
| 28.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN | 1 | HKEx | ||
| 23.09. | LEADS BIOLABS-B (09887): 2026 INTERIM REPORT | 1 | HKEx | ||
| 21.09. | LEADS BIOLABS CO., LTD.: Leads Biolabs' Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations | 6 | GlobeNewswire (USA) | ||
| 21.09. | LEADS BIOLABS-B (09887): VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY ... | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| MBX BIOSCIENCES | 55,94 | 0,00 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| ERASCA | 15,655 | -0,03 % | Erasca GAAP EPS of -$0.15 misses by $0.01 | ||
| TANGO THERAPEUTICS | 25,500 | 0,00 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| VIR BIOTECHNOLOGY | 9,970 | +0,10 % | Vir Biotechnology: HDV-Daten lassen Aktie explodieren | Vir Biotechnology sorgt mit gleich zwei positiven Nachrichten im Bereich Hepatitis Delta für Aufsehen. Sowohl die ersten Ergebnisse der zulassungsrelevanten Phase-3-Studie als auch erweiterte Phase-2-Daten... ► Artikel lesen | |
| CG ONCOLOGY | 74,36 | -0,05 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,140 | -0,07 % | Jefferies reiterates Summit Therapeutics stock rating after FDA setback | ||
| PRAXIS PRECISION MEDICINES | 327,68 | -0,14 % | Praxis Precision Medicines stellt Markteinführungspläne für zwei Medikamentenkandidaten vor | ||
| RELAY THERAPEUTICS | 18,090 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,810 | +0,02 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,690 | 0,00 % | ADMA Biologics (NDQ:ADMA): The Antibody Factory, The Short Seller Attack, And The Earnings That Followed | ||
| ABSCI | 8,440 | -0,12 % | Absci anticipates interim 13-week ABS-201 pattern hair loss data next month as it plans mid-2027 endometriosis Phase 2 start | ||
| PRIME MEDICINE | 4,270 | 0,00 % | Prime Medicine closes $143.7M public offering at $3.50/share | ||
| AMYLYX PHARMACEUTICALS | 30,300 | +0,03 % | Amylyx: Avexitide-Studie erreicht primären Endpunkt bei postbariatrischer Hypoglykämie | ||
| PARABILIS MEDICINES | 28,430 | 0,00 % | Liberty Defense zahlt Darlehen über 2,45 Millionen US-Dollar an Parabilis vollständig zurück |